July 1984 she received a total dose of 500 mg/r2 of cisplatin and 250 mg/M2 of doxorubicin (adriamycin). Three weeks after the completion of chemotherapy pins and needles developed in the hands and feet, which spread over several weeks to the elbows and knees. Associated with this was clumsiness of the hands and feet and unsteadiness of gait. Hearing became worse around the middle of the course of chemotherapy. One month after stopping chemotherapy on nodding her head forward small electric shock sensations were felt down both shins.
In October 1984 there was no evidence of recurrent malignancy. The When examined in December 1984 he had metastatic tumour in lung and liver. Hearing was slightly impaired for whispering but there were no other cranial nerve abnormalities. Strength was normal except for minimal weakness of finger abduction only. Reflexes were absent in limbs and abdomen. Light touch sensation was decreased at the fingers and absent in the feet. Pin prick produced hyperaesthesia in these areas. Vibration sense was absent in the lower arms and in both legs. Position testing impaired at the fingers and absent at toes and ankles and normal at wrists, knees and hips. Heel-toe testing was unsteady. Unstressed gait was normal but on turning and heel-toe walking marked unsteadiness occurred. Rhombergs testing was positive. Pseudoathetoid movements were present in extended fingers. Nerve conduction studies showed an absence of right sural, ulnar, median and radial sensory potentials. Right median forearm conduction was normal (52 m/s) as was distal median motor latency (3-2 ms). Ulnar motor forearm conduction velocity was slightly slowed (47 m/s) but from above to below the elbow it was normal (45 m/s). Distal ulnar motor latency was also normal (2-7 ms). In the legs lateral popliteal motor conduction was slowed (36 m/s from fibula head to ankle, 21 m/s popliteal fossa to fibula head). Distal motor latency to extensor digitorum brevis was normal (5.4 ms). Significant decrement in the amplitude of the surface recorded proximal evoked muscle action potential was present (1-5 mV at ankle and fibula head, 0.5 mV at popliteal fossa). Medial popliteal distal motor latency and motor conduction velocity from popliteal fossa to ankle were both normal (5.0 97 m/s and 43 m/s respectively), but significant decrement in amplitude of the surface recorded evoked muscle potential from abductor hallucis was present (2.5 mV at ankle, 1 mV at popliteal fossa). Electromyographic examination of right abductor pollicus brevis, extensor communis digitorum and vastus medialis was normal. The tibialis anterior motor units on weak effort were excessively polyphasic and prolonged and at full effort their amplitude was greatly increased (up to 12 mV). Enlargement of these motor units was confirmed by computerised analysis of the interference pattern.7 CSF was not examined and cervical radiculography was not performed.
All patients had light or no alcohol consumption; B12, random glucose, urea and electrolytes and serum VDRLs were normal.
Discussion
Transient parathesiae or "electric shocks" in the limbs brought about by flexing the neck, known as Lhermitte's or "Barber's Chair" sign indicates a lesion in the spinal cord, probably in the dorsal columns.8 Thus all three patients had clinical evidence of myelopathy.
At presentation these patients had extensive malignant. disease, but no evidence of myelopathy. This did not develop until chemotherapy had been completed, at a time when one patient had active disease but the other two had no detectable disease. There was no evidence of recurrent tumour nor any other demonstrable lesion near the spinal cord nor intercurrent conditions known to cause myelopathy. One patient was being treated with radiotherapy when he first noted Lhermitte's sign, but the spinal cord was not in the radiation field and neither of the other two patients had been treated with radiotherapy.9 When Lhermitte's sign develops following a clearly defined episode of trauma to the spinal cord a variable latent period of one to two and a half months has been observed.'0 In our patients the sign developed 4 to 8 weeks after completion of their chemotherapy. The timing and lack of other obvious causes suggested that these myelopathies had been caused by cytotoxic chemotherapy.
In animal experiments doxorubicin (adriamycin) can cause necrosis of dorsal root ganglion cells."' In clinical use both vinblastine and cisplatin cause autonomic and peripheral neuropathy.'2 '3 Etoposide (VP16) may cause peripheral neuropathy.'3 Bleomycin does not seem to be neurotoxic. In seeking a single drug for these myelopathies, cisplatin appears the only likely candidate since it was the only drug with which all three patients were treated. The case of a child who died having been treated with eleven courses of cisplatin has been reported.'4 Post mortem histology showed marked degeneration and gliosis of the dorsal col- There are many clinical features of these patients reminiscent of subacute sensory neuropathy associated with carcinoma.2' 22 In this disorder dorsal column degeneration also occurs, though Lhermitte's sign has not been described. Even though cisplatin has been in use for more than twelve years, there have been only two previous reports of cisplatin-induced myelopathy. One report'6 described in passing "a brief accentuation of paresthesias in the anterior legs and dorsa of the feet in response to flexion of the neck" and another'4 reported histological changes in the dorsal columns following cisplatin. Only the first of our three patients volunteered the information that "electric shocks" occurred with head nodding. The relevant history was elicited from the other two by direct (but not leading) questioning. None of the patients appeared to be distressed by their symptom which they regarded as a minor curiosity. Cisplatin neuropathy is probably dose related.' 1623 Since its introduction the doses of the drug given in various treatment regimes have been progressively increased, so possibly the risk of myelopathy has been increasing with this.
The latent period between cessation of treatment and development of further clinical signs indicates that by the time a patient on treatment with cisplatin has clinical signs of neurotoxicity, stopping the drug may not prevent further deterioration and disability. Cisplatin is highly effective in the treatment of some tumours which are invariably fatal if inadequately treated. Under these circumstances the decision to discontinue treatment is not taken lightly and it is probable that patients suffering from cisplatin neurotoxicity will be seen in increasing numbers.
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